Form 4: Cara Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christopher Posner, CEO of Cara Therapeutics, sold 3,668 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Summary
- Christopher Posner, the CEO of Cara Therapeutics, sold 3,668 shares of the company's common stock on November 4, 2024.
- The sale was executed at a price of $0.29 per share.
- The transaction was conducted under a pre-arranged 'sell to cover' arrangement adopted on November 2, 2022, to satisfy tax withholding obligations triggered by the vesting of restricted stock units.
- Following the transaction, Posner directly owns 168,768 shares of Cara Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document describes a routine stock sale to cover tax obligations, which is neither particularly positive nor negative.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when restricted stock units vest.
Stakeholder Impact
- The sale of shares by the CEO could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.
Key Dates
| Date | Description |
|---|---|
| 2022-11-02 | Date the Reporting Person adopted the Rule 10b5-1 arrangement. |
| 2024-11-04 | Date of the stock sale transaction. |
| 2024-11-06 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.